ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Large Molecule Drug Substance CDMO Market Research Report 2024
Published Date: December 2024
|
Report Code: QYRE-Auto-14N18750
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Large Molecule Drug Substance CDMO Market Research Report 2024
BUY CHAPTERS

Global Large Molecule Drug Substance CDMO Market Research Report 2024

Code: QYRE-Auto-14N18750
Report
December 2024
Pages:96
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Company
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
Wuxi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals

Large Molecule Drug Substance CDMO Market Size

The global market for Large Molecule Drug Substance CDMO was valued at US$ 24220 million in the year 2023 and is projected to reach a revised size of US$ 59060 million by 2030, growing at a CAGR of 13.1% during the forecast period.

Large Molecule Drug Substance CDMO Market

Large Molecule Drug Substance CDMO Market

A Large Molecule Drug Substance CDMO (Contract Development and Manufacturing Organization) is a specialized company that provides outsourced services for the development and manufacturing of large molecule drugs, also known as biologics. These are complex, biologically-derived drugs, typically proteins, antibodies, or nucleic acids, which are used in the treatment of a wide variety of diseases, including cancer, autoimmune disorders, and genetic conditions.
North American market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Large Molecule Drug Substance CDMO in SMBs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Large Molecule Drug Substance CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Large Molecule Drug Substance CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Large Molecule Drug Substance CDMO.
The Large Molecule Drug Substance CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Large Molecule Drug Substance CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Large Molecule Drug Substance CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Large Molecule Drug Substance CDMO Market Report

Report Metric Details
Report Name Large Molecule Drug Substance CDMO Market
Accounted market size in year US$ 24220 million
Forecasted market size in 2030 US$ 59060 million
CAGR 13.1%
Base Year year
Forecasted years 2024 - 2030
Segment by Type
Segment by Application
  • SMBs
  • Large Companies
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Large Molecule Drug Substance CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Large Molecule Drug Substance CDMO Market growing?

Ans: The Large Molecule Drug Substance CDMO Market witnessing a CAGR of 13.1% during the forecast period 2024-2030.

What is the Large Molecule Drug Substance CDMO Market size in 2030?

Ans: The Large Molecule Drug Substance CDMO Market size in 2030 will be US$ 59060 million.

Who are the main players in the Large Molecule Drug Substance CDMO Market report?

Ans: The main players in the Large Molecule Drug Substance CDMO Market are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals

What are the Application segmentation covered in the Large Molecule Drug Substance CDMO Market report?

Ans: The Applications covered in the Large Molecule Drug Substance CDMO Market report are SMBs, Large Companies

What are the Type segmentation covered in the Large Molecule Drug Substance CDMO Market report?

Ans: The Types covered in the Large Molecule Drug Substance CDMO Market report are Cell and Gene Therapies, Antibodies, Vaccines, Other

Recommended Reports

CDMO Market Landscape

Biologics & Antibody CDMO

Gene & Cell Therapy CDMO

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Other
1.3 Market by Application
1.3.1 Global Large Molecule Drug Substance CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Large Molecule Drug Substance CDMO Market Perspective (2019-2030)
2.2 Global Large Molecule Drug Substance CDMO Growth Trends by Region
2.2.1 Global Large Molecule Drug Substance CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Large Molecule Drug Substance CDMO Historic Market Size by Region (2019-2024)
2.2.3 Large Molecule Drug Substance CDMO Forecasted Market Size by Region (2025-2030)
2.3 Large Molecule Drug Substance CDMO Market Dynamics
2.3.1 Large Molecule Drug Substance CDMO Industry Trends
2.3.2 Large Molecule Drug Substance CDMO Market Drivers
2.3.3 Large Molecule Drug Substance CDMO Market Challenges
2.3.4 Large Molecule Drug Substance CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Large Molecule Drug Substance CDMO Players by Revenue
3.1.1 Global Top Large Molecule Drug Substance CDMO Players by Revenue (2019-2024)
3.1.2 Global Large Molecule Drug Substance CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Large Molecule Drug Substance CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Large Molecule Drug Substance CDMO Revenue
3.4 Global Large Molecule Drug Substance CDMO Market Concentration Ratio
3.4.1 Global Large Molecule Drug Substance CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Large Molecule Drug Substance CDMO Revenue in 2023
3.5 Global Key Players of Large Molecule Drug Substance CDMO Head office and Area Served
3.6 Global Key Players of Large Molecule Drug Substance CDMO, Product and Application
3.7 Global Key Players of Large Molecule Drug Substance CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Large Molecule Drug Substance CDMO Breakdown Data by Type
4.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Type (2019-2024)
4.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (2025-2030)
5 Large Molecule Drug Substance CDMO Breakdown Data by Application
5.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Application (2019-2024)
5.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Large Molecule Drug Substance CDMO Market Size (2019-2030)
6.2 North America Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
6.4 North America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Large Molecule Drug Substance CDMO Market Size (2019-2030)
7.2 Europe Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
7.4 Europe Large Molecule Drug Substance CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Large Molecule Drug Substance CDMO Market Size (2019-2030)
8.2 Asia-Pacific Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Large Molecule Drug Substance CDMO Market Size (2019-2030)
9.2 Latin America Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
9.4 Latin America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Large Molecule Drug Substance CDMO Market Size (2019-2030)
10.2 Middle East & Africa Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Large Molecule Drug Substance CDMO Introduction
11.1.4 Lonza Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Large Molecule Drug Substance CDMO Introduction
11.2.4 Catalent Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.2.5 Catalent Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Details
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Large Molecule Drug Substance CDMO Introduction
11.3.4 Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.3.5 Samsung Biologics Recent Development
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.4.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Introduction
11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Large Molecule Drug Substance CDMO Introduction
11.5.4 Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 WuXi Biologics
11.6.1 WuXi Biologics Company Details
11.6.2 WuXi Biologics Business Overview
11.6.3 WuXi Biologics Large Molecule Drug Substance CDMO Introduction
11.6.4 WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.6.5 WuXi Biologics Recent Development
11.7 Recipharm
11.7.1 Recipharm Company Details
11.7.2 Recipharm Business Overview
11.7.3 Recipharm Large Molecule Drug Substance CDMO Introduction
11.7.4 Recipharm Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.7.5 Recipharm Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Large Molecule Drug Substance CDMO Introduction
11.8.4 Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Large Molecule Drug Substance CDMO Introduction
11.9.4 AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.9.5 AGC Biologics Recent Development
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Details
11.10.2 Rentschler Biopharma Business Overview
11.10.3 Rentschler Biopharma Large Molecule Drug Substance CDMO Introduction
11.10.4 Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.10.5 Rentschler Biopharma Recent Development
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Details
11.11.2 KBI Biopharma Business Overview
11.11.3 KBI Biopharma Large Molecule Drug Substance CDMO Introduction
11.11.4 KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.11.5 KBI Biopharma Recent Development
11.12 Siegfried
11.12.1 Siegfried Company Details
11.12.2 Siegfried Business Overview
11.12.3 Siegfried Large Molecule Drug Substance CDMO Introduction
11.12.4 Siegfried Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.12.5 Siegfried Recent Development
11.13 Aenova Group
11.13.1 Aenova Group Company Details
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Large Molecule Drug Substance CDMO Introduction
11.13.4 Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.13.5 Aenova Group Recent Development
11.14 GenScript
11.14.1 GenScript Company Details
11.14.2 GenScript Business Overview
11.14.3 GenScript Large Molecule Drug Substance CDMO Introduction
11.14.4 GenScript Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.14.5 GenScript Recent Development
11.15 ProBioGen
11.15.1 ProBioGen Company Details
11.15.2 ProBioGen Business Overview
11.15.3 ProBioGen Large Molecule Drug Substance CDMO Introduction
11.15.4 ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.15.5 ProBioGen Recent Development
11.16 Northway Biotech
11.16.1 Northway Biotech Company Details
11.16.2 Northway Biotech Business Overview
11.16.3 Northway Biotech Large Molecule Drug Substance CDMO Introduction
11.16.4 Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.16.5 Northway Biotech Recent Development
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Details
11.17.2 3P Biopharmaceuticals Business Overview
11.17.3 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Introduction
11.17.4 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
11.17.5 3P Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Company
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
Wuxi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
List of Tables
 Table 1. Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Cell and Gene Therapies
 Table 3. Key Players of Antibodies
 Table 4. Key Players of Vaccines
 Table 5. Key Players of Other
 Table 6. Global Large Molecule Drug Substance CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Large Molecule Drug Substance CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 8. Global Large Molecule Drug Substance CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 9. Global Large Molecule Drug Substance CDMO Market Share by Region (2019-2024)
 Table 10. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 11. Global Large Molecule Drug Substance CDMO Market Share by Region (2025-2030)
 Table 12. Large Molecule Drug Substance CDMO Market Trends
 Table 13. Large Molecule Drug Substance CDMO Market Drivers
 Table 14. Large Molecule Drug Substance CDMO Market Challenges
 Table 15. Large Molecule Drug Substance CDMO Market Restraints
 Table 16. Global Large Molecule Drug Substance CDMO Revenue by Players (2019-2024) & (US$ Million)
 Table 17. Global Large Molecule Drug Substance CDMO Market Share by Players (2019-2024)
 Table 18. Global Top Large Molecule Drug Substance CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Large Molecule Drug Substance CDMO as of 2023)
 Table 19. Ranking of Global Top Large Molecule Drug Substance CDMO Companies by Revenue (US$ Million) in 2023
 Table 20. Global 5 Largest Players Market Share by Large Molecule Drug Substance CDMO Revenue (CR5 and HHI) & (2019-2024)
 Table 21. Global Key Players of Large Molecule Drug Substance CDMO, Headquarters and Area Served
 Table 22. Global Key Players of Large Molecule Drug Substance CDMO, Product and Application
 Table 23. Global Key Players of Large Molecule Drug Substance CDMO, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 26. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2019-2024)
 Table 27. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 28. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2025-2030)
 Table 29. Global Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 30. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2019-2024)
 Table 31. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 32. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2025-2030)
 Table 33. North America Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 34. North America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 35. North America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 36. Europe Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 37. Europe Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 38. Europe Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 39. Asia-Pacific Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 40. Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 41. Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2025-2030) & (US$ Million)
 Table 42. Latin America Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 43. Latin America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 45. Middle East & Africa Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 46. Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 47. Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 48. Lonza Company Details
 Table 49. Lonza Business Overview
 Table 50. Lonza Large Molecule Drug Substance CDMO Product
 Table 51. Lonza Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 52. Lonza Recent Development
 Table 53. Catalent Company Details
 Table 54. Catalent Business Overview
 Table 55. Catalent Large Molecule Drug Substance CDMO Product
 Table 56. Catalent Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 57. Catalent Recent Development
 Table 58. Samsung Biologics Company Details
 Table 59. Samsung Biologics Business Overview
 Table 60. Samsung Biologics Large Molecule Drug Substance CDMO Product
 Table 61. Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 62. Samsung Biologics Recent Development
 Table 63. FUJIFILM Diosynth Biotechnologies Company Details
 Table 64. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 65. FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Product
 Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 67. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 68. Boehringer Ingelheim Company Details
 Table 69. Boehringer Ingelheim Business Overview
 Table 70. Boehringer Ingelheim Large Molecule Drug Substance CDMO Product
 Table 71. Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 72. Boehringer Ingelheim Recent Development
 Table 73. WuXi Biologics Company Details
 Table 74. WuXi Biologics Business Overview
 Table 75. WuXi Biologics Large Molecule Drug Substance CDMO Product
 Table 76. WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 77. WuXi Biologics Recent Development
 Table 78. Recipharm Company Details
 Table 79. Recipharm Business Overview
 Table 80. Recipharm Large Molecule Drug Substance CDMO Product
 Table 81. Recipharm Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 82. Recipharm Recent Development
 Table 83. Thermo Fisher Scientific Company Details
 Table 84. Thermo Fisher Scientific Business Overview
 Table 85. Thermo Fisher Scientific Large Molecule Drug Substance CDMO Product
 Table 86. Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 87. Thermo Fisher Scientific Recent Development
 Table 88. AGC Biologics Company Details
 Table 89. AGC Biologics Business Overview
 Table 90. AGC Biologics Large Molecule Drug Substance CDMO Product
 Table 91. AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 92. AGC Biologics Recent Development
 Table 93. Rentschler Biopharma Company Details
 Table 94. Rentschler Biopharma Business Overview
 Table 95. Rentschler Biopharma Large Molecule Drug Substance CDMO Product
 Table 96. Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 97. Rentschler Biopharma Recent Development
 Table 98. KBI Biopharma Company Details
 Table 99. KBI Biopharma Business Overview
 Table 100. KBI Biopharma Large Molecule Drug Substance CDMO Product
 Table 101. KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 102. KBI Biopharma Recent Development
 Table 103. Siegfried Company Details
 Table 104. Siegfried Business Overview
 Table 105. Siegfried Large Molecule Drug Substance CDMO Product
 Table 106. Siegfried Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 107. Siegfried Recent Development
 Table 108. Aenova Group Company Details
 Table 109. Aenova Group Business Overview
 Table 110. Aenova Group Large Molecule Drug Substance CDMO Product
 Table 111. Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 112. Aenova Group Recent Development
 Table 113. GenScript Company Details
 Table 114. GenScript Business Overview
 Table 115. GenScript Large Molecule Drug Substance CDMO Product
 Table 116. GenScript Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 117. GenScript Recent Development
 Table 118. ProBioGen Company Details
 Table 119. ProBioGen Business Overview
 Table 120. ProBioGen Large Molecule Drug Substance CDMO Product
 Table 121. ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 122. ProBioGen Recent Development
 Table 123. Northway Biotech Company Details
 Table 124. Northway Biotech Business Overview
 Table 125. Northway Biotech Large Molecule Drug Substance CDMO Product
 Table 126. Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 127. Northway Biotech Recent Development
 Table 128. 3P Biopharmaceuticals Company Details
 Table 129. 3P Biopharmaceuticals Business Overview
 Table 130. 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Product
 Table 131. 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 132. 3P Biopharmaceuticals Recent Development
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Large Molecule Drug Substance CDMO Picture
 Figure 2. Global Large Molecule Drug Substance CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Large Molecule Drug Substance CDMO Market Share by Type: 2023 VS 2030
 Figure 4. Cell and Gene Therapies Features
 Figure 5. Antibodies Features
 Figure 6. Vaccines Features
 Figure 7. Other Features
 Figure 8. Global Large Molecule Drug Substance CDMO Market Size by Application (2024-2030) & (US$ Million)
 Figure 9. Global Large Molecule Drug Substance CDMO Market Share by Application: 2023 VS 2030
 Figure 10. SMBs Case Studies
 Figure 11. Large Companies Case Studies
 Figure 12. Large Molecule Drug Substance CDMO Report Years Considered
 Figure 13. Global Large Molecule Drug Substance CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 14. Global Large Molecule Drug Substance CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Large Molecule Drug Substance CDMO Market Share by Region: 2023 VS 2030
 Figure 16. Global Large Molecule Drug Substance CDMO Market Share by Players in 2023
 Figure 17. Global Top Large Molecule Drug Substance CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Large Molecule Drug Substance CDMO as of 2023)
 Figure 18. The Top 10 and 5 Players Market Share by Large Molecule Drug Substance CDMO Revenue in 2023
 Figure 19. North America Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 20. North America Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 21. United States Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 22. Canada Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Europe Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Europe Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 25. Germany Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. France Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 27. U.K. Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 28. Italy Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. Russia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. Nordic Countries Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Asia-Pacific Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Asia-Pacific Large Molecule Drug Substance CDMO Market Share by Region (2019-2030)
 Figure 33. China Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. Japan Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. South Korea Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. Southeast Asia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 37. India Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Australia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. Latin America Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 40. Latin America Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 41. Mexico Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. Brazil Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. Middle East & Africa Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Middle East & Africa Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 45. Turkey Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Saudi Arabia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. UAE Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Lonza Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 49. Catalent Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 50. Samsung Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 52. Boehringer Ingelheim Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 53. WuXi Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 54. Recipharm Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 56. AGC Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 57. Rentschler Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 58. KBI Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 59. Siegfried Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 60. Aenova Group Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 61. GenScript Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 62. ProBioGen Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 63. Northway Biotech Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Biological Drug CDMO Market Research Report 2024
Global Small Molecules CDMO Services Market Research Report 2024
Global Biologics CDMO Services Market Research Report 2024
Global Small Molecule Drug CDMO Services Market Research Report 2024
Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biomacromolecule CDMO Market Research Report 2024
Global Chemical CDMO Market Research Report 2024
Global Contract Dose Manufacturing Market Insights Forecast to 2030
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Global Full Service CDMO Market Research Report 2024
Global Chemical Drug CDMO Market Research Report 2024
Global Pharmaceutical CDMO Market Research Report 2025
Global Topical Drugs CDMO Market Research Report 2025
Pharmaceutical CMO and CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biopharmaceutical CDMO Market Research Report 2025
Biologics CDMO Market
Global Antibody Drug CDMO Service Market Research Report 2024
Global Biopharmaceutical and Bio CDMO Market Research Report 2024
Pharmaceutical CDMO Pharmaceutical Contract Development and Manufacturing Organization Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions